- Home
- SWVL vs BLRX Comparison
SWVL vs BLRX Comparison
Compare SWVL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWVL | BLRX |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United Arab Emirates | Israel |
| Employees | 284 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SWVL | BLRX |
|---|---|---|
| Price | $1.57 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 43.2K | 9.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $2.30 |
| 52 Week High | $4.99 | $7.77 |
Technical Indicators
Market Signals| Indicator | SWVL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 42.05 |
| Support Level | $1.34 | $2.66 |
| Resistance Level | $3.83 | $3.11 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 54.29 | 26.15 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.